Neurofenix
Neurofenix is a virtual care provider delivering at-home neurorehabilitation programs for stroke and neurological patients, combining an FDA-registered NeuroBall sensor device with a NeuroPlatform for remote monitoring, gamified therapy, and licensed-therapist virtual sessions, sold to ACOs, hospitals, and patients.
- Company typePrivate
- Founded2016
- HeadquartersLondon, United Kingdom
- Headcount11–50
- GTM typeB2B and B2C
- OfferingServices
What Neurofenix does
Neurofenix is a virtual care provider focused on at-home neurorehabilitation, primarily for stroke survivors and patients with other neurological conditions such as brain injury, TBI, and chronic neurological disease. The company's offering combines a proprietary sensor-based hardware device (the NeuroBall, FDA-registered as a Class I medical device) with a software platform (the NeuroPlatform) that enables Remote Therapeutic Monitoring, clinician dashboards, gamified therapy sessions, and HIPAA-compliant documentation. Patients enroll in 8 to 16-week personalized programs delivered by licensed therapists via weekly virtual sessions, with the NeuroBall supporting high-repetition, high-intensity upper-limb exercises at home; the company cites clinical evidence of 20x higher therapy intensity versus in-person care and outcomes such as 84% of patient goals met at program completion.
The business operates across three revenue streams: Medicare-covered virtual therapy program subscriptions, NeuroBall hardware sales and rentals, and Remote Therapeutic Monitoring services. Go-to-market is multi-channel, combining direct-to-patient onboarding, hospital and provider partnerships, ACO partnerships (including a relationship with FLAACOs), and e-commerce hardware sales. A provider-facing layer — the Neurofenix Partner Dashboard and Bifurcator screening tool (via NeurofenixHub.com) — supports referral management and candidate identification without requiring ePHI at intake. Neurofenix is incorporated in Florida as Neurofenix, Inc., with origins in London where it was founded in 2016 by Guillem Singla Buxarrais (CEO) and Dimitrios Athanasiou (CTO), and raised a $7 million Series A led by AlbionVC in August 2022 to fund its US expansion and clinical trials.
Neurofenix firmographics
Firmographics- Name
- Neurofenix
- Legal name
- Neurofenix, Inc.
- Website
- https://neurofenix.com
- Company type
- Private
- Founded year
- 2016
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Neurofenix is a virtual care provider delivering at-home neurorehabilitation programs for stroke and neurological patients, combining an FDA-registered NeuroBall sensor device with a NeuroPlatform for remote monitoring, gamified therapy, and licensed-therapist virtual sessions, sold to ACOs, hospitals, and patients.
- Ownership category
- akta.pro rank
Neurofenix industry classification
Industry- Product category
- Virtual Neurorehabilitation Services
- NAICS
- Home Health Care Services (62161), Offices of Physical, Occupational and Speech Therapists, and Audiologists (62134)
- SIC
- Services-Home Health Care Services (8082), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Neurology Telemedicine Platforms (HLALAGAC)
- akta.pro secondary industries
- Digital Rehabilitation & Physical Therapy Therapeutics (HLACANAJ), Neurological Rehabilitation Therapy In-Home (e.g., Stroke, Parkinson’s) (HSABADAE), Stroke & Vascular Neurology (HLAKAIAG)
Keywords
Where Neurofenix is headquartered
LocationHeadquarters
- HQ city
- London
- HQ country
- United Kingdom
- HQ region
- Europe
Offices1 record
Markets served
Neurofenix business model
Business model- GTM type
- B2B and B2C
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Supply Chain
Revenue model
- Virtual Therapy Program Subscriptions: Neurofenix provides 8 to 16-week personalized virtual therapy programs delivered by licensed therapists. Programs are covered by Medicare and include weekly 1:1 virtual sessions, remote monitoring, and personalized care plans. Revenue is generated through healthcare reimbursement and potentially direct contracts with ACOs and health systems.
- NeuroBall Device Sales and Rentals: The NeuroBall device is available through multiple purchase options including month-to-month rental and full purchase. Part number NBL-01T 0006 D indicates specific device configurations.
- Remote Therapeutic Monitoring (RTM) Services: Continuous monitoring services using the NeuroPlatform and Remote Therapeutic Monitoring system. Clinicians track adherence and progress through the dashboard, enabling timely interventions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Unit Pricing | Pay-as-you-go | Flexible NeuroBall purchase options |
| Subscription | Monthly | Medicare-covered virtual therapy programs |
Go-to-market motion2 records
Distribution channels4 records
Marketing channels7 records
Neurofenix product offering
Product offeringCore offering
Neurofenix delivers tech-enabled virtual neurorehabilitation programs for stroke survivors and other neurological patients, bundling the FDA-registered NeuroBall sensor device with the NeuroPlatform software for remote therapeutic monitoring, clinician dashboards, and gamified therapy. Patients enroll in 8 to 16-week personalized programs delivered remotely by licensed therapists, with continuous 1:1 support, weekly virtual sessions, and at-home high-intensity exercises covered by Medicare. The company also contracts with ACOs, hospitals, and providers to extend neuro rehab services into the home and reduce readmissions.
Product overview
Neurofenix offers a neurorehabilitation platform combining hardware and software to deliver virtual care for stroke and brain injury patients. The core offering centers on the NeuroBall sensor-based therapy device paired with the NeuroPlatform software for remote monitoring. Additional modules include the Partner Dashboard for healthcare providers and the Bifurcator screening tool. The company delivers personalized 8 to 16-week virtual therapy programs featuring high-intensity exercises, weekly therapist sessions, and continuous remote monitoring—all designed for at-home use.
Differentiator
Problem solved
Functional benefit
Brands
- NeuroBall™: A sensor-based arm and hand therapy device for neurorehabilitation, FDA registered as a Class I medical device. The NeuroBall enables patients to perform exercises aimed at improving motor skills and functional ability from home.
- NeuroPlatform
- Neurofenix Partner Dashboard
- Neurofenix Bifurcator™
Products and services
- NeuroBall FDA-registered Class I medical device: a wireless, battery-powered, portable sensor-based arm and hand therapy device for upper-limb neurorehabilitation. Designed for stroke survivors and neurological patients at home or bedside, detecting small movements to enable high-repetition therapy.
- Virtual Neuro Rehab Program An 8 to 16-week personalized virtual therapy program for stroke survivors and neurological patients combining weekly 1:1 sessions with licensed therapists, remote therapeutic monitoring, gamified home exercises, and a Home Neuro Rehab Kit. Medicare-covered and reimbursed.
- NeuroPlatform HIPAA-compliant software platform and clinician dashboard providing real-time patient progress tracking, therapy adherence monitoring, remote therapeutic monitoring, and clinical reporting for virtual neuro rehab programs.
- Neurofenix Partner Dashboard Provider-facing dashboard for healthcare partners to manage patient referrals, monitor real-time progress, coordinate care transitions, and support discharge planning for neurological patients.
- Neurofenix Bifurcator No-registration screening tool that helps providers quickly assess and identify ideal candidates for virtual neuro rehab, without requiring ePHI or patient signup.
Quantifiable outcome
- 20x more therapy intensity at home than in-person therapy
- +6 more outcomes
Companies that use Neurofenix
Customer profileNamed customers5 records
Segments4 records
Ideal customer profiles3 records
Neurofenix technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Neurofenix partnerships and signals
Strategic signalPartnerships
Seven partnerships are on record, tiered supporting and flagship.
- Brunel UniversitysupportingClinical research collaboration to validate the effectiveness of the NeuroBall in hospital and home settings. Multiple clinical trials conducted.
- FLAACOssupportingPartnership with Florida Association of Accountable Care Organizations for joint webinars and education on virtual care driving savings for ACOs.
- Spaulding Rehabilitation HospitalflagshipFeatured collaboration with Spaulding Rehabilitation Hospital, one of the top rehabilitation hospitals in the US, as part of their clinical advisory network.
- Shirley Ryan AbilityLabflagshipFeatured collaboration with Shirley Ryan AbilityLab (formerly Rehabilitation Institute of Chicago), ranked as top physical medicine and rehabilitation hospital.
- Emory HealthcareflagshipFeatured collaboration with Emory Healthcare, a leading academic health system, as part of their clinical network.
- Intermountain HealthcareflagshipFeatured collaboration with Intermountain Healthcare, a major integrated health system, as part of their clinical advisory network.
- Burke Rehabilitation HospitalflagshipFeatured collaboration with Burke Rehabilitation Hospital, a leading rehabilitation hospital in New York, as part of their clinical network.
Scale indicators10 records
Recent moves7 records
Expansion highlights6 records
Neurofenix competitors and assessment
Company assessmentBroad incumbents
- Bioventus: Publicly-traded orthobiologics and medical device company (owns former Bioness portfolio) providing neurostimulation and rehabilitation devices for stroke and orthopedic recovery — overlapping patient population with a much broader product portfolio.
- Sword Health: AI-powered digital MSK and pelvic health therapy platform with virtual clinicians and wearable sensors. Comparable virtual-care-plus-device business model at substantially larger scale, expanding into adjacent therapy areas.
- Hinge Health: Largest digital musculoskeletal therapy platform, serving employers and health plans with virtual PT, wearable sensors, and coaches. Operates in adjacent rehab categories with far greater scale and capital, increasingly moving into neuro and post-acute care.
Direct peers
- Flint Rehab: Sells sensor-based home neurorehabilitation devices (MusicGlove, FitMi) targeting stroke survivors — direct hardware analog to Neurofenix's NeuroBall with overlapping patient population and at-home therapy positioning.
- MindMaze: Digital neurotherapeutics platform combining gamified therapy, motion capture, and clinical decision support across stroke, TBI, and other neurological conditions — a more capitalized direct competitor with overlapping clinical targets.
- Constant Therapy Health: Digital therapy platform for speech, cognitive, and physical rehabilitation of neurological patients, with a direct-to-patient and clinical-channel model highly comparable to Neurofenix's NeuroPlatform + virtual therapist offering.
- Saebo: Specialty medical device company offering upper-limb orthoses and electrical stimulation devices for stroke rehabilitation, with a comparable focus on functional arm/hand recovery for post-stroke patients.
- Bionik Laboratories: Develops robotic and sensor-based rehabilitation technologies for patients with neurological impairments, sharing Neurofenix's focus on at-home and clinical neurorehab technology.
Emerging players
- Neurolutions: Developer of an FDA-cleared EEG-based brain-computer interface for post-stroke hand rehabilitation. Comparable in patient population and clinical focus, but applies a different (neurostimulation/neuromodulation) technology approach rather than sensor-based gamified therapy.
Regional players
- Tyromotion: Austria-based manufacturer of robotic and sensor-based rehabilitation devices for neurological patients, primarily serving European clinics. Comparable technology stack and patient focus, with limited US commercial overlap with Neurofenix.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights7 records
Customer concentration
Neurofenix social profiles
Digital presenceNeurofenix compliance and trust
Trust signalCompliance2 records
Neurofenix financial estimates
Financial estimateRevenue estimate
Valuation estimate
Neurofenix leadership team
Management profileNumber of profiles
Profiles8 records
Neurofenix funding detail
Funding detailFunding overview
Funding rounds5 records
Investors6 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Neurofenix M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Neurofenix
What does Neurofenix do?
Neurofenix delivers tech-enabled virtual neurorehabilitation programs for stroke survivors and other neurological patients, bundling the FDA-registered NeuroBall sensor device with the NeuroPlatform software for remote therapeutic monitoring, clinician dashboards, and gamified therapy. Patients enroll in 8 to 16-week personalized programs delivered remotely by licensed therapists, with continuous 1:1 support, weekly virtual sessions, and at-home high-intensity exercises covered by Medicare. The company also contracts with ACOs, hospitals, and providers to extend neuro rehab services into the home and reduce readmissions.
Is Neurofenix a public or private company?
Neurofenix is a private company. It is classified as venture growth investor backed and is currently operating.
When was Neurofenix founded?
Neurofenix was founded in 2016. It employs 11 to 50 people.
Where is Neurofenix based?
Neurofenix is headquartered in London, United Kingdom, in the Europe region.
How does Neurofenix make money?
Three revenue lines are on record. Virtual Therapy Program Subscriptions are the primary driver. The others are neuroBall Device Sales and Rentals and remote Therapeutic Monitoring (RTM) Services.
Who are Neurofenix's main competitors?
Broad incumbents on record are Bioventus, Sword Health and Hinge Health. Direct peers are Flint Rehab, MindMaze, Constant Therapy Health, Saebo and Bionik Laboratories. Neurolutions is listed as an emerging player. Tyromotion is listed as a regional player.
Does Neurofenix have an API?
No public API is recorded for Neurofenix.
What industry is Neurofenix in?
Neurofenix's product category is Virtual Neurorehabilitation Services. Its primary akta.pro industry code is HLALAGAC, Neurology Telemedicine Platforms, with a secondary code of HLACANAJ, Digital Rehabilitation & Physical Therapy Therapeutics. Its NAICS code is 62161 and its SIC code is 8082.